People default image

Jenna Fontenot

Associate
Miami
About

Jenna Fontenot is a corporate lawyer and former neurosurgery nurse, representing clients in a broad range of transactions and other corporate and securities law matters. 

Jenna advises public company clients across industries on SEC reporting and disclosure requirements, shareholder activism and engagement, and other securities law and stock exchange compliance matters. She also counsels public companies on a variety of corporate governance matters, including board composition and procedures, environmental, social and governance (ESG), internal and disclosure controls, insider trading and other topics. Jenna also represents investment banks as well as public and private companies, primarily in the life sciences and technology industries, in a variety of transactions including IPOs and other primary and secondary offerings, private placements, transactions involving SPACs, tender offers, mergers and acquisitions, and other transactions.

Areas of FocusCorporateHealthcareLife Sciences TransactionsESGEquity Capital MarketsFinancial ServicesLife SciencesMergers and AcquisitionsPrivate EquityTechnologyCapital Markets and Public Company Advisory
Bar admissionsNew YorkFlorida

EXPERIENCE

Jenna has represented:

  • Cantor Fitzgerald & Co. and the other initial purchasers in connection with a $650 million convertible notes offering by CleanSpark, Inc.
  • Cantor Fitzgerald & Co. and the other initial purchasers in connection with a $500 million offering of convertible notes by TeraWulf Inc.
  • Calliditas Therapeutics AB in connection with its acquisition by Asahi Kasei Corporation in a $1.1 billion tender offer.
  • Cantor Fitzgerald & Co. as dealer manager in connection with a tender offer and consent solicitation by Zura Bio Ltd.
  • Quantum-Si Incorporated, in connection with its $75 million at-the-market offering.
  • Cantor Fitzgerald & Co. as dealer manager in connection with a tender offer and consent solicitation by Marti Technologies, Inc.
  • NewAmsterdam Pharma in its $726 million business combination with Frazier Lifesciences.*
  • Evercore and William Blair as lead book-runners in the Nasdaq IPO of MiNK Therapeutics.*
  • LanzaTech in its $2.2 billion deSPAC merger.*
  • Goldman Sachs, Morgan Stanley and other underwriters in an upsized $201 million follow-on offering by Bicycle Therapeutics.*
  • Adit EdTech in a $3.3 billion deSPAC merger with Griid Infrastructure.*
  • Selecta Biosciences in a $39 million follow-on offering.*
  • Cantor Fitzgerald and RBC as underwriters in a $100 million at-the-market offering and a $30 million follow-on offering for MindMed, Inc.*
  • Jefferies and Cowen as underwriters in connection with Quotient Ltd.’s follow-on and at-the-market offerings.*
  • Cantor Fitzgerald in connection with Marker Therapeutics’ at-the-market offering.*
  • Global Pharmaceutical and other life sciences companies in connection with SEC public reporting and corporate governance matters.

*Matters handled prior to DLA Piper

Pro Bono

Jenna counsels charitable organizations in connection with corporate matters.
Education
  • J.D., Tulane University
    cum laude
    Senior Editor, Tulane Maritime Law Journal
  • B.S.N., Southeastern Louisiana University

Bylines

Media Mentions

Prior Experience

Prior to practicing law, Jenna practiced as a registered neurosurgery nurse at the Tulane Center for Clinical Neurosciences.

My latest insights

News

DLA Piper advises Cantor Fitzgerald & Co. in Forward Industries Inc.’s US$1.65 billion...

12 September 2025 .1 minute read

News

DLA Piper advises initial purchasers in upsized US$122.5 million convertible notes...

15 July 2025 .1 minute read

Publication
Abstract building

Reminders and new disclosure requirements for the 2025 proxy season

27 March 2025 .1 minute read

View All
CallvCardLinkedInPrint

Connect

Phone

+1 305 423 8577
(Work, Miami)